Johnson & Johnson Opens London Innovation Centre
The big pharma giant Johnson & Johnson has begun opening innovation centres with the aim to accelerate the best early-stage science in the world and to advance the development of new healthcare solutions.
The project is part of J&J’s “broader innovation strategy to advance human health through collaboration with the world's leading scientists and entrepreneurs,” said Paul Stoffels, Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, at J&J.
“We are looking forward to collaborating within the UK, home to one of the world's thriving life sciences ecosystems,” said Stoffels. “Science and technology hold unprecedented opportunities to transform healthcare, and by investing and collaborating in ground-breaking science we can deliver transformational innovations in healthcare to people across the world,” he added.
The three other innovation hubs will be located in Boston, San Francisco and, later this year, in Shanghai. Each city was selected for its “robust life sciences community,” says J&J. London was chosen as a site because of its proximity with a number of excellent universities, research councils and research charities, high concentration of small and medium-sized biotechnology enterprises (SMEs), the venture capital community in the City of London for raising funds and its good infrastructure links, adds the Department of Health.
Read Related Articles On Healthcare Global
- World's First Flying Hospital Takes To The Skies
- Space Tech Could Improve Chances Of Cancer Recovery
- Qatar's Five Star Hospital Of The Future
The London Innovation Centre will bring together ‘the best talent,’ Patrick Verheyen, who heads up the centre, told Pharma Times. It will house science and technology experts with board expertise in developing new solutions and products, and will have local deal-making capabilities to flexibly adapt deal structures to match early-stage opportunities.
This will enable scientists, entrepreneurs and emerging companies to deliver innovation via collaboration with experts who can drive partnerships across J&J's pharmaceutical, medical device and diagnostics and consumer healthcare companies, says the firm.
“Our on-the-ground proximity to regional scientists and entrepreneurs will allow us to build the strong personal relationships that underlie the most successful collaborations and investment deals,” Verheyen added.
The centre will focus on technologies in key areas: dementia; cancer; infectious diseases; immunology; biomarkers for disease; and devices to make surgery quicker, faster and safer.
Welcoming the new London Centre, Health Secretary Jeremy Hunt said: “Britain has a worldwide reputation for excellence in innovation - the investment by J&J here demonstrates this.”
“I want to give doctors and nurses the time and space to deliver patient-centred care - to do this we need to be innovative,” he went on. “Our universities are among the very best in the world and our scientists and clinicians are second to none. I am determined to cement and accelerate our position as the number one place for health and pharmaceutical companies to invest and grow and hopefully develop the next generation of medical breakthroughs.”
J&J is the world's largest healthcare company, with total sales of $67.2 billion in 2012.
Read The Press Release From Johnson & Johnson
- Rising cancer drug costs lead to doctor protests against Big PharmaHospitals
- Big Pharma: Taking a Drug from Theory to Research and DevelopmentProcurement & Supply Chain
- The Dark Side of Big Pharma: How Marketing to Doctors Really WorksProcurement & Supply Chain
- Big Pharma vs. MedTech in Spain - Which Industry Will Come Out on Top in 2020?Technology & AI